

From: [Director_PTABDecision_Review](#)
To: "Trask, Andrew"; ialy@schiffhardin.com; Aly, Imron T.; salesh.patel@afslaw.com; AFS-Fresenius-aflibercept865IPR@afslaw.com; Berl, David; Argall, Arthur
Subject: RE: IPR2025-01268: Document(s) Filed - Fresenius Kabi SwissBioSim GmbH v. Regeneron Pharmaceuticals, Inc.- Director Review Request
Date: Monday, December 22, 2025 10:31:00 AM

Counsel,

Patent Owner's request is granted. Patent Owner is authorized to submit a response to Petitioner's request for Director Review by January 6, 2026.

Thank you.

From: Trask, Andrew <atrask@wc.com>
Sent: Sunday, December 21, 2025 2:07 PM
To: Director_PTABDecision_Review <Director_PTABDecision_Review@uspto.gov>
Cc: ialy@schiffhardin.com; Aly, Imron T. <imron.aly@afslaw.com>; salesh.patel@afslaw.com; AFS-Fresenius-aflibercept865IPR@afslaw.com; Berl, David <DBerl@wc.com>; Argall, Arthur <aargall@wc.com>
Subject: RE: IPR2025-01268: Document(s) Filed - Fresenius Kabi SwissBioSim GmbH v. Regeneron Pharmaceuticals, Inc.- Director Review Request

You don't often get email from atrask@wc.com. [Learn why this is important](#)

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Dear Honorable Director:

With apologies, the email below contained a typographical error. The parties' requested extended deadline is January 6, **2026**.

Respectfully submitted,

Andrew Trask
Counsel for Patent Owner

cc: Counsel for Petitioner

Andrew Trask | Williams & Connolly LLP | 202-434-5023 | atrask@wc.com

From: Trask, Andrew
Sent: Sunday, December 21, 2025 13:59
To: 'Director_PTABDecision_Review' <Director_PTABDecision_Review@uspto.gov>
Cc: ialy@schiffhardin.com; 'Aly, Imron T.' <imron.aly@afslaw.com>; salesh.patel@afslaw.com; 'AFS-

Fresenius-aflibercept865IPR@afslaw.com' <AFS-Fresenius-aflibercept865IPR@afslaw.com>; Berl, David <DBerl@wc.com>; Argall, Arthur <aargall@wc.com>

Subject: RE: IPR2025-01268: Document(s) Filed - Fresenius Kabi SwissBioSim GmbH v. Regeneron Pharmaceuticals, Inc.- Director Review Request

Dear Honorable Director:

On Friday, December 19, 2025, the Director authorized Patent Owner Regeneron to file a response to Petitioner Fresenius's request for Director Review within five business days, i.e., by Monday, December 29. Patent Owner and Petitioner have conferred, and in light of the upcoming holidays both parties have agreed to request from the Director an extension of the deadline for Patent Owner's response until January 6, 2025. Accordingly, Patent Owner, on behalf of both parties, hereby respectfully requests an unopposed extension until January 6, 2025, of the deadline to file Patent Owner's response to Petitioner's Director Review request.

Respectfully submitted,

Andrew Trask
Counsel for Patent Owner

cc: Counsel for Petitioner

Andrew Trask | Williams & Connolly LLP | 202-434-5023 | atrask@wc.com

From: Director_PTABDecision_Review <Director_PTABDecision_Review@uspto.gov>

Sent: Friday, December 19, 2025 16:32

To: Berl, David <DBerl@wc.com>; ialy@schiffhardin.com; Trask, Andrew <atrask@wc.com>; Argall, Arthur <aargall@wc.com>; sailsh.patel@afslaw.com

Subject: RE: IPR2025-01268: Document(s) Filed - Fresenius Kabi SwissBioSim GmbH v. Regeneron Pharmaceuticals, Inc.- Director Review Request

Counsel,

Petitioner's request for Director Review has been received in the above-referenced case. Patent Owner is authorized to submit a response limited to the issues raised in the Director Review request, of no more than 15 pages, to be filed within five business days of this email. Any such response must be filed in P-TACTS, i.e., by selecting the "Other: Other" paper type and the paper must be titled "Authorized Response to Director Review Request" or it may not be considered. No new evidence is permitted. No further briefing is authorized at this time.

The Director will determine whether review will be granted or denied and the parties will be notified of the result of the Director Review request.

Thank you.

This message and any attachments are intended only for the addressee and may contain information that is privileged and confidential. If you have received this message in error, please do not read, use, copy, distribute, or disclose the contents of the message and any attachments. Instead, please delete the message and any attachments and notify the sender immediately. Thank you.